Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response

BACKGROUND: Despite the proven efficacy of vedolizumab (VDZ) for ulcerative colitis (UC) and Crohn’s disease (CD), suboptimal response is commonly encountered. However, data regarding the effectiveness of dose intensification (by interval shortening) to achieve response are limited. OBJECTIVES: We e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Frontline Gastroenterol
Main Authors: Samaan, Mark A, Birdi, Siddharth, Morales, Maria Sierra, Honap, Sailish, Tamilarasan, Aravind Gokul, Cunningham, Georgina, Koumoutsos, Ioannis, Ray, Shuvra, Mawdsley, Joel, Anderson, Simon H C, Sanderson, Jeremy, Irving, Peter M
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Colorectal
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7223295/
https://ncbi.nlm.nih.gov/pubmed/32419909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2019-101259
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados